Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. - Wikidata - wikimedia - TriplyDB

Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo.

Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo.

http://www.wikidata.org/entity/Q42938990

about

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia A Perspective of Immunotherapy for Prostate Cancer Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects Immunotherapy in Chronic Lymphocytic Leukaemia (CLL)Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy Novel immunotherapies in lymphoid malignancies Lymphoma Immunotherapy: Current Status CD19-redirected chimeric antigen receptor-modified T cells: a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL)Adoptive immunotherapy for acute leukemia: New insights in chimeric antigen receptors Chimeric Antigen Receptor- and TCR-Modified T Cells Enter Main Street and Wall Street CAR T Cell Therapy: A Game Changer in Cancer Treatment CARs in chronic lymphocytic leukemia -- ready to drive Progress and prospects for engineered T cell therapies Immune reconstitution in chronic lymphocytic leukemia Novel immunotherapies for hematologic malignancies Adoptive T-cell therapy for Leukemia Using gene therapy to manipulate the immune system in the fight against B-cell leukemias CD19 as an attractive target for antibody-based therapy Chimeric antigen receptor therapy for cancer Current translational and clinical practices in hematopoietic cell and gene therapy Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges Effective adoptive immunotherapy of triple-negative breast cancer by folate receptor-alpha redirected CAR T cells is influenced by surface antigen expression level Remote control of therapeutic T cells through a small molecule-gated chimeric receptor.PSMA-specific CAR-engineered T cells eradicate disseminated prostate cancer in preclinical models A novel ex vivo isolation and expansion procedure for chimeric antigen receptor engrafted human T cells Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer Vaccination Catch me if you can: Leukemia Escape after CD19-Directed T Cell Immunotherapies Exploiting IL-17-producing CD4+ and CD8+ T cells to improve cancer immunotherapy in the clinic Recent advances and novel treatment paradigms in acute lymphocytic leukemia Recent advances in T-cell engineering for use in immunotherapy CD19-Chimeric Antigen Receptor T Cells for Treatment of Chronic Lymphocytic Leukaemia and Acute Lymphoblastic Leukaemia CAR therapy: the CD19 paradigm CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia Engineering T Cells to Functionally Cure HIV-1 Infection Smart CARs engineered for cancer immunotherapy Designing chimeric antigen receptors to effectively and safely target tumors Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma Redirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123+ Tumors

P2860

Q24594920-A1CFF0A7-94B0-4779-A73D-329E23DFAA3E Q24632975-045BAF96-D997-43CD-884C-3353E920834D Q26741277-346D4D9D-A7AC-4C28-98D3-4C16914085F4 Q26753082-CF4B1EBD-BBE0-438D-AFF8-3DB429C3FE2A Q26768154-A99D1FFA-3B45-4BCF-A08C-4BA1628433FC Q26773309-5DB58B3A-66F6-41BC-878B-3DD98386C9B4 Q26777394-4F7458E9-C58E-47A4-A180-8BC61A27F21A Q26782902-FB9EBF93-3F44-4B52-B5E9-AE5583113671 Q26783433-EAE9359E-A985-4D09-8A4C-C0125A626EF4 Q26795540-6559EF68-3DE8-4505-A772-E7D8ECADC6DC Q26799357-794029E4-E15E-428D-9EAF-4F94950A6E96 Q26822769-AC1C0D5F-F136-4365-BAC7-8DDEBD6DDBFF Q26830526-AA843960-6EED-498B-B766-6907015E63B0 Q26852923-FF4050EC-472A-488B-8DA8-63679C1FE01C Q26865561-56B0F9F9-4A3F-4232-8D34-B4858A180FAA Q27004436-F5F8A214-6B39-4C9F-BDD5-1959D8BC7586 Q27006934-FF7968C7-2B71-42AC-9E25-9129763CB5C3 Q27011297-5C96F550-C8DF-4D92-82CE-69D228892567 Q27011836-1CF8181C-3990-4D14-BFF3-C1BE86D0CAD0 Q27013599-5DBF3ABC-AD29-49F5-9D89-0A92EF529057 Q27024456-13E47B4C-9445-45E1-9B9C-477057FE4D9F Q27025300-CA77C545-41C3-4F7F-8E27-69EA3783E3CE Q27300701-D2995E19-DDE3-43CD-B42D-946D8E3F93A7 Q27330599-D15F9EB7-025E-4650-B04A-1FB9F05F2CE3 Q27339832-16567A9C-E1FA-4CE2-8270-693E6CE2C02A Q27345360-3E0AE613-82F0-43B0-96F5-AFA16D48009C Q28068378-01CBE2D8-0D64-4CF9-8DE5-06188576D5A0 Q28072131-D6BBB123-F06C-49A9-B0F5-CAF14AFF36C0 Q28075992-6530CF2B-3312-409C-9221-C25C7CB0DCCF Q28078076-59786940-4E02-4811-A42D-F4DA26DD2704 Q28080312-B11A03CB-D196-434D-8499-B3572AF5594B Q28081600-1CAD71BD-BCD1-4766-AD55-6B18FC19809C Q28081642-DB0B2601-51FF-4E4B-93BC-D490BA4A1EF6 Q28084879-44695F2D-5B27-4D47-9B9C-4FCCB98B89A7 Q28086801-374FEAA6-CB36-4BE8-8C9A-49A42AD50C19 Q28087236-F471FD8A-8D02-4314-8387-0D4E9757BBE2 Q28088526-502D332B-8F2A-4E54-A66E-6A223032E5B5 Q28276800-096640E1-A293-47FA-8CC3-8B729C2EAEF6 Q28537688-B9E335F4-C06B-4A47-93DE-AC4465BAB6F7 Q28553650-F1CD48CA-B931-49B4-AC41-FB4806A57005

P2860

Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo.

http://www.wikidata.org/entity/Q42938990

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

2009年论文

@zh

2009年论文

@zh-cn

name

Chimeric receptors containing ...... antileukemic efficacy in vivo.

@en

Chimeric receptors containing ...... antileukemic efficacy in vivo.

@nl

type

label

Chimeric receptors containing ...... antileukemic efficacy in vivo.

@en

Chimeric receptors containing ...... antileukemic efficacy in vivo.

@nl

prefLabel

Chimeric receptors containing ...... antileukemic efficacy in vivo.

@en

Chimeric receptors containing ...... antileukemic efficacy in vivo.

@nl

P1433

Q42938990-67F2B688-74EA-4153-96B1-0CB85500670E

P1476

Q42938990-94A331A9-D854-4CE8-953D-1987AA4799E5

P2093

Q42938990-071DD53B-D22E-4141-AE14-13EC69B0AEFD

Q42938990-24AC916B-809C-449C-9590-F509048F3F81

Q42938990-2AC65299-9E4E-4A51-A566-8D088BA1548C

Q42938990-53789620-83D9-4489-8D2A-76157BBF8005

Q42938990-53A72D9B-5DD7-4234-BEEE-DDF99B1C6148

Q42938990-54E49A6F-F006-4C78-B574-EB7306FD5C09

Q42938990-6481F7CD-7262-46D1-BEF7-8C9183A342D6

Q42938990-6D325544-1457-44D7-A84E-EF2A9EFFB948

Q42938990-6F19C868-4499-47A2-985C-F3CAB6154341

Q42938990-AB75932E-99EC-48AB-AC0B-899FEF5C6F86

P2860

Q42938990-03D6074A-B5E0-4A8F-9776-D28D5B6C10BA

Q42938990-08230BC0-053A-448F-8AA3-33F75F27A1D6

Q42938990-09D8F528-0E7A-441E-8352-4CF31D33A891

Q42938990-14DB2E74-6A89-48FC-9EA6-14A98176C6CE

Q42938990-17E00784-AB2F-4D31-99A4-5DDD1C942EAA

Q42938990-18BC453A-4B9D-4028-8D41-A5940965CBCE

Q42938990-1E493310-9E75-4DA5-A011-0BDCB2C2B3DD

Q42938990-232615D7-23AC-48B4-9805-CA19AF9F7F75

Q42938990-2AB6A3A5-7626-451D-80BC-0658F16C88A6

Q42938990-3074F158-0891-4DEB-A6C3-2A5AC04DF8A2

P304

Q42938990-E14324CA-0883-49F0-A12C-1A01B9DF3EF6

P31

Q42938990-F523AA5B-4814-4B3A-88CB-4A103D489A9F

P356

Q42938990-2E411111-5233-469E-908B-2A88BCFC7A3E

P433

Q42938990-EC3F3A09-7B43-4173-B1EE-A91D72F5AD06

P478

Q42938990-34E4ACE0-EADA-4630-9D4C-EF055FB18DC3

P50

Q42938990-DC07F79B-A50F-437D-BC33-18E3F180DC2E

P577

Q42938990-89F5A303-B24C-4C60-918B-5E634A580946

P5875

Q42938990-FE48FAC9-DFAE-4082-B9DA-C792EC9ACDCE

P698

Q42938990-BB614B02-AFFB-466E-9E15-8D7753A72184

P932

Q42938990-659832AF-1F6A-4155-B826-43A76DFC5100

P356

P1433

Molecular Therapy

P1476

Chimeric receptors containing ...... antileukemic efficacy in vivo.

@en

P2093

Brian Gloss

http://www.w3.org/2001/XMLSchema#string

Carl H June

http://www.w3.org/2001/XMLSchema#string

Carmine Carpenito

http://www.w3.org/2001/XMLSchema#string

Dario Campana

http://www.w3.org/2001/XMLSchema#string

David Teachey

http://www.w3.org/2001/XMLSchema#string

Gwendolyn K Binder

http://www.w3.org/2001/XMLSchema#string

Gwenn Danet-Desnoyers

http://www.w3.org/2001/XMLSchema#string

Jonathan D Fish

http://www.w3.org/2001/XMLSchema#string

Mehdi Lakhal

http://www.w3.org/2001/XMLSchema#string

Michael C Milone

http://www.w3.org/2001/XMLSchema#string

P2860

Gene transfer in humans using a conditionally replicating lentiviral vector

CD19, the earliest differentiation antigen of the B cell lineage, bears three extracellular immunoglobulin-like domains and an Epstein-Barr virus-related cytoplasmic tail

Co-stimulatory members of the TNFR family: keys to effective T-cell immunity?

A third-generation lentivirus vector with a conditional packaging system

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

Molecular portraits of B cell lineage commitment.

Targeted elimination of prostate cancer by genetically directed human T lymphocytes.

CD137 stimulation delivers an antigen-independent growth signal for T lymphocytes with memory phenotype

The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL

Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors.

P304

1453-1464

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MT.2009.83

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-04-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24346433

http://www.w3.org/2001/XMLSchema#string

P698

19384291

http://www.w3.org/2001/XMLSchema#string

P932

2805264

http://www.w3.org/2001/XMLSchema#string